文献检索

查找使用阿拉丁产品的科研文献

检索与阿拉丁产品相关的同行评审论文、DOI、PubMed 编号、期刊、作者、CAS 号及研究领域。

科研影响力快照

与阿拉丁产品相关的已发表科研成果

在搜索之前,这些指标可帮助访客快速了解产品关联科研的规模与质量。

346,364+ SCI 论文 与阿拉丁产品引用相关
2,295,288.15 总影响因子 匹配文献记录中影响因子的总和
81.20 最高期刊影响因子 匹配期刊中的最高 IF
6.63 平均期刊影响因子 匹配文献的平均 IF

参考指标 指标基于阿拉丁文献引用数据库及期刊影响因子记录。文献关联仅供科研参考,请以原始文献为准。

热门产品

视图 列表 网格

1 项目

设置提升方向
Tilapia lake virus
AQUACULTURE · 2025 · IF 3.9

Baicalin, a promising therapeutic drug against tilapia lake virus (TiLV) infection

Yun-Yao Tu,Jie Leng,Na Zhang,Qin Yang,Hong-Yu Tang,Cheng-Ke Zhu,Wei-Wei Zeng,Ming-Ji Lv,Song Zhu

Tilapia lake virus (TiLV) has caused serious deadly epidemics and still remains a devastating threat to tilapia aquaculture worldwide, with no practical therapeutic measures. In the study, anti-TiLV activities of 22 kinds of drugs are checked to develop a potential strategy for TiLV control. Safety of the selected drugs to E-11 cells is firstly evaluated to determine their maximum safe concentration (MSC). For preliminary screening in vitro , three 10-fold gradient-diluted drug concentrations (10 −2 , 10 −1 and 10 0 * MSC) are prepared. Baicalin shows the strongest inhibition activity on TiLV-induced cytopathic effects with an inhibition rate close to 80 % at 100 mg/L, and followed by favipiravir and amantadine hydrochloride. Baicalin can completely suppress viral infection at 200 mg/L as verification by Western blot and RT-qPCR analysis, and the 90 % inhibitory concentrations of baicalin on TiLV is 61.33 mg/L. Baicalin shows no obvious anti-TiLV activity by pre-treatment of E-11 cells before TiLV infection, while the infectivity of TiLV is significantly weakened following baicalin treatment, and baicalin has a strong anti-TiLV activity at the post-entry stage of TiLV infection. Besides, baicalin shows no obvious effects on the TiLV attachment to E-11 cells, but has significant inhibition on TiLV multiplication. Therefore, baicalin may have a direct virucidal effect, and/or block the viral genome translation and replication. For anti-TiLV activity evaluation in vivo , baicalin can improve the survival rate of TiLV-infected Nile tilapia ( Oreochromis niloticus ) to 81.8 % following treatment with 10 μg/g baicalin for 3 times, while that was 54.5 % for TiLV-infected tilapia without baicalin treatment. Moreover, the viral titers in liver of TiLV-infected tilapia are generally decreased after baicalin treatment. Results so far indicated that baicalin is a promising therapeutic drug against TiLV infection, providing a potential strategy for TiLV control and promoting the healthy development of tilapia aquaculture.

研究领域: 水产养殖学 · 病毒学 · 药物开发
✓ 已验证 DOI 高影响因子
查看原文 查看 PubMed
已复制

文献关联基于可获得的产品、CAS、DOI 及引用记录。收录不代表作者或出版方对阿拉丁产品的背书,请以原始文献为准。